For HCPsIntended for HCPs.

Clinical Intelligence for Modern Medicine.

The integrated, institutional-grade registry trusted by US-licensed practitioners for evidence-based clinical data, drug information, and peer-reviewed drug updates.

Clinical Resources

Drug updates, reference data, and specialist-led coverage.

Recent Clinical Updates

Latest Drug & Specialty Updates

View All

Specialty Coverage

Therapeutic-area updates for clinical review.

All Specialties

Drug Information

FDA drug records and prescribing context.

Review drug records, NDC references, dosage tools, and interaction resources alongside clinical coverage.

FDA data

Drug Reference

Drug approvals, labels, and clinical context.

Access structured FDA label data, dosage references, NDC records, interactions, and prescribing context.

Clinical Coverage

Additional Drug Updates

Neurology

CGRP Inhibitors: Erenumab, Fremanezumab, and Galcanezumab for Migraine Prevention

3h ago|3 min read|By Dr. Aditi Kulkarni
Neurology

FDA Approves Zycubo for Menkes Disease: 78% Reduction in Mortality Risk

3h ago|3 min read|By Dr. Aditi Kulkarni
Pulmonology

FDA Approves Depemokimab for Severe Asthma: Once-Yearly Injection for Eosinophilic Phenotype

3h ago|3 min read|By Dr. Nikhil Chatterjee
Hematology

FDA Approves Fitusiran for Hemophilia: Antithrombin Lowering Therapy for Patients 12 and Older

3h ago|3 min read|By Dr. Shruti Pandey
Dermatology

FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis: BE VIVID Trial Results

Apr 30|3 min read|By Dr. Divya Agarwal
Otolaryngology

FDA Approves Dupilumab for Allergic Fungal Rhinosinusitis: First Indication for AFRS

Apr 30|3 min read|By Editorial Team
Endocrinology

FDA Submits NDA for CagriSema: Fixed-Dose Combination of Cagrilintide and Semaglutide for Obesity Management

Apr 30|3 min read|By Dr. Amit Desai
Oncology

WHO Updates Guidelines on BRCA Testing for Breast and Ovarian Cancer Screening

Apr 30|3 min read|By Dr. Meera Pillai
Neurology

FDA Approves Ofatumumab and Natalizumab for High Efficacy in Multiple Sclerosis Treatment

Apr 30|3 min read|By Dr. Vikram Patel
Endocrinology

FDA Approves Foundayo: New GLP-1 Pill for Obesity Management

Apr 30|3 min read|By Dr. Amit Desai
Endocrinology

FDA Approves Zepbound for Weight Management: Key Differences from Mounjaro

Apr 30|3 min read|By Dr. Amit Desai
Cardiology

SGLT2 Inhibitors: Heart Failure and Kidney Protection Evidence in 2024

Apr 30|3 min read|By Dr. Kavya Sharma
Neurology

FDA Approves Donanemab for Alzheimer: 27% Cognitive Decline Reduction

Apr 30|3 min read|By Dr. Aditi Kulkarni
Neurology

CGRP Inhibitors: Erenumab, Fremanezumab, Galcanezumab, and Atogepant for Migraine Prevention

Apr 30|3 min read|By Dr. Aditi Kulkarni
Neurology

FDA Approves Copper Histidinate for Menkes Disease: 78% Survival Benefit in Pediatric Patients

Apr 30|3 min read|By Dr. Vikram Patel
Pulmonology

FDA Approves Depemokimab for Severe Asthma: Eosinophilic Phenotype Treatment

Apr 30|3 min read|By Dr. Nikhil Chatterjee
Hematology

FDA Approves Fitusiran for Hemophilia: New Antithrombin Therapy for Patients

Apr 30|3 min read|By Dr. Shruti Pandey
Dermatology

FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis: 75% Skin Clearance in BE VIVID Trial

Apr 29|3 min read|By Dr. Rohan Gupta
Infectious Disease

FDA Authorizes Nirmatrelvir-Ritonavir (Paxlovid) for COVID-19: 89% Hospitalization Reduction in EPIC-HR Trial

Apr 29|3 min read|By Dr. Simran Kohli
Neurology

FDA Approves Atogepant for Episodic Migraine Prevention: 50% Reduction in Monthly Migraine Days

Apr 29|3 min read|By Dr. Aditi Kulkarni
Otolaryngology

FDA Approves Dupilumab for Allergic Fungal Rhinosinusitis: Improved Sinus Opacification in Patients

Apr 29|3 min read|By Editorial Team
Endocrinology

FDA Submits NDA for CagriSema: Cagrilintide-Semaglutide Combo for Obesity Management

Apr 29|3 min read|By Dr. Amit Desai
Oncology

USPSTF Updates BRCA Testing Guidelines: Who to Screen for Breast and Ovarian Cancer

Apr 29|3 min read|By Dr. Rahul Verma